Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1137-1146

  Bagnoli, Marina ^a   Canevari, Silvana ^a   Califano, Daniela ^b   Losito, Simona ^b   Maio, Massimo Di ^b   Raspagliesi, Francesco ^a   Carcangiu, Maria Luisa ^a   Toffoli, Giuseppe ^c   Cecchin, Erika ^c   Sorio, Roberto ^c   Canzonieri, Vincenzo ^c   Russo, Daniela ^b   Scognamiglio, Giosué ^b   Chiappetta, Gennaro ^b   Baldassarre, Gustavo ^c   Lorusso, Domenica ^a   Scambia, Giovanni ^d   Zannoni, Gian Franco ^d   Savarese, Antonella ^e   Carosi, Mariantonia ^e   Scollo, Paolo ^f   Breda, Enrico ^g   Murgia, Viviana ^h   Perrone, Francesco ^b   Pignata, Sandro ^b   De Cecco, Loris ^a   Mezzanzanica, Delia ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f CANNIZZARO HOSPITAL   (Italy)

^g SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^h SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; SURVIVAL PREDICTION; SURVIVAL TIME; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; DISEASE COURSE; ENDOMETRIAL NEOPLASMS; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE; VALIDATION STUDY; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84995961219     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30108-5     Document Type: Article

References (45)

1. 1 Jayson, GC, Kohn, EC, Kitchener, HC, Ledermann, JA, Ovarian cancer. Lancet 384 (2014), 1376–1388.
2. 2 Vaughan, S, Coward, JI, Bast, RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11 (2011), 719–725.
3. 3 Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
4. 4 Tothill, RW, Tinker, AV, George, J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14 (2008), 5198–5208.
5. 5 Kang, J, D'Andrea, AD, Kozono, D, A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 104 (2012), 670–681.
6. 6 Tan, TZ, Miow, QH, Huang, RY, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 5 (2013), 983–998.
7. 7 Verhaak, RG, Tamayo, P, Yang, JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123 (2013), 517–525.
8. 8 Riester, M, Wei, W, Waldron, L, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst, 106, 2014, dju048.
9. 9 Konecny, GE, Wang, C, Hamidi, H, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst, 106, 2014, dju249.
10. 10 Iorio, MV, Visone, R, Di Leva, G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 67 (2007), 8699–8707.
11. 11 Marchini, S, Cavalieri, D, Fruscio, R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 12 (2011), 273–285.
12. 12 Vecchione, A, Belletti, B, Lovat, F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA 110 (2013), 9845–9850.
13. 13 Pignata, S, Scambia, G, Ferrandina, G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29 (2011), 3628–3635.
14. 14 Bagnoli, M, De Cecco, L, Granata, A, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2 (2011), 1265–1278.
15. 15 Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
16. 16 Callari, M, Dugo, M, Musella, V, et al. Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One, 7, 2012, e45105.
17. 17 Edgar, R, Domrachev, M, Lash, AE, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30 (2002), 207–210.
18. 18 Gentleman, RC, Carey, VJ, Bates, DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol, 5, 2004, R80.
19. 19 Heider, A, Alt, R, virtualArray: a R/bioconductor package to merge raw data from different microarray platforms. BMC Bioinformatics, 14, 2013, 75.
20. 20 Johnson, WE, Li, C, Rabinovic, A, Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 (2007), 118–127.
21. 21 Bair, E, Tibshirani, R, Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol, 2, 2004, E108.
22. 22 De Cecco, L, Bossi, P, Locati, L, Canevari, S, Licitra, L, Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. Ann Oncol 25 (2014), 1628–1635.
23. 23 Taylor, JM, Ankerst, DP, Andridge, RR, Validation of biomarker-based risk prediction models. Clin Cancer Res 14 (2008), 5977–5983.
24. 24 Radmacher, MD, McShane, LM, Simon, R, A paradigm for class prediction using gene expression profiles. J Comput Biol 9 (2002), 505–511.
25. 25 Crijns, AP, Fehrmann, RS, de, JS, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med, 6, 2009, e24.
26. 26 Kurman, RJ, Carcangiu, ML, Herrington, CS, Young, RH, (eds.) WHO classification of tumors of female reproductive organs, 4th edn., 2014, International Agency for Research on Cancer, Lyon.
27. 27 Shih, I-M, Kurman, RJ, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004), 1511–1518.
28. 28 Van Peer, G, Lefever, S, Anckaert, J, et al. miRBase Tracker: keeping track of microRNA annotation changes. Database (Oxford), 2014, 2014, bau080.
29. 29 Stuart, GC, Kitchener, H, Bacon, M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21 (2011), 750–775.
30. 30 Lu, J, Getz, G, Miska, EA, et al. MicroRNA expression profiles classify human cancers. Nature 435 (2005), 834–838.
31. 31 Mariani, M, McHugh, M, Petrillo, M, et al. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget 5 (2014), 4855–4867.
32. 32 Zhang, S, Lu, Z, Unruh, AK, et al. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 13 (2015), 393–401.
33. 33 Yang, D, Sun, Y, Hu, L, et al. Integrated analyses identify a master MicroRNA regulatory network for the mesenchymal subtype in serous ovarian Cancer. Cancer Cell 23 (2013), 186–199.
34. 34 Zhang, JX, Mai, SJ, Huang, XX, et al. MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of beta-catenin signaling. Ann Oncol 25 (2014), 2196–2204.
35. 35 Sun, Y, Guo, F, Bagnoli, M, et al. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer 34 (2015), 28–40.
36. 36 Liu, G, Sun, Y, Ji, P, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 233 (2014), 308–318.
37. 37 Sun, Y, Hu, L, Zheng, H, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235 (2014), 25–36.
38. 38 Liu, G, Yang, D, Rupaimoole, R, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst, 107, 2015, djv108.
39. 39 Park, SM, Gaur, AB, Lengyel, E, Peter, ME, The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22 (2008), 894–907.
40. 40 Mezzanzanica, D, Bagnoli, M, De Cecco, L, Valeri, B, Canevari, S, Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 42 (2010), 1262–1272.
41. 41 Boisen, MK, Dehlendorff, C, Linnemann, D, et al. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line capecitabine and oxaliplatin with or without bevacizumab. PLoS One, 9, 2014, e109430.
42. 42 Fischer, KR, Durrans, A, Lee, S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
43. 43 Micheel, CM, Nass, SJ, Omenn, GS, (eds.) Commitee on the review of omics-based tests for predicting patient outcomes in clinical trials; Board on health care service; Board on health sciences policy; Institute of medicine; Evolution of translational OMICS: lessons learned and the path foreward, 2012, National Academies Press, Washington, DC.
44. 44 Altman, DG, McShane, LM, Sauerbrei, W, Taube, SE, Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med, 9, 2012, e1001216.
45. 45 Pignata, S, Scambia, G, Katsaros, D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15 (2014), 396–405.